Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study

NCT07824960 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT07824960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study
Lead sponsor
University of Virginia
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
April 30, 2030
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreatic carcinoma, pancreatic cancer, pdac - pancreatic ductal adenocarcinoma